2016年ASAS-EULAR中轴型脊柱关节炎管理推荐更新
该推荐由ASAS与EULAR基于两项系统文献综述及任务组共识制定,共5项总体原则和13条推荐,覆盖中轴型脊柱关节炎的个性化治疗、非药物管理、NSAIDs一线地位、生物制剂使用及手术等。
要点
- NSAIDs是axSpA一线药物治疗;对至少两种NSAIDs疗效不佳或不耐受且有高疾病活动者考虑bDMARDs。
- bDMARDs包括TNFi和IL-17i,当前实践从TNFi开始,失败后可换用另一种TNFi或IL-17i。
- 持续缓解者可考虑bDMARD减量但不应停药;不推荐糖皮质激素和传统合成DMARDs用于以中轴受累为主的患者。
核心结论
- 2016年ASAS-EULAR推荐为axSpA全程管理提供最新指导,整合了AS和TNFi使用推荐为适用于全部axSpA患者的一套推荐。
研究设计与样本
- 按照EULAR标准化操作程序,先进行两项系统文献综述收集2009年以来所有药物和非药物治疗证据,经指导组讨论和任务组展示后制定总体原则和推荐,并通过非正式投票达成共识。
主要发现
- 共达成5项总体原则和13条推荐。
- 前3条推荐涉及个性化医疗包括治疗目标和监测。
- 推荐5描述NSAIDs作为一线药物治疗的核心作用。
- 推荐9指出对至少两种NSAIDs使用后(或不耐受/禁忌)仍高疾病活动且CRP升高和/或MRI明确炎症和/或影像学骶髂关节炎证据的患者使用bDMARDs包括TNFi和IL-17i。
- 推荐10建议TNFi失败后换用另一种TNFi或IL-17i;推荐11建议持续缓解者可考虑bDMARD减量但非停药。
关键数值与推荐
- 推荐9要求患者高疾病活动且至少两种NSAIDs使用后(或不耐受/禁忌),并具备CRP升高和/或MRI明确炎症和/或影像学骶髂关节炎证据。
- 推荐6-8定义镇痛药的有限作用,并否定糖皮质激素和传统合成DMARDs用于以中轴受累为主的axSpA患者。
- 推荐10建议TNFi失败后换用另一种TNFi或IL-17i。
- 推荐11建议持续缓解者可考虑bDMARD减量但不应停药。
- 推荐12和13涉及手术和脊柱骨折。
临床怎么用
- 临床应首先采用NSAIDs治疗axSpA,对符合条件的高疾病活动患者启动bDMARDs,通常从TNFi开始。
- TNFi治疗失败后可换用另一种TNFi或IL-17i。
- 持续缓解患者可考虑bDMARD减量但不应停药,以中轴受累为主者不推荐糖皮质激素和传统合成DMARDs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.
引用
- van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. PMID: 28087505. doi:10.1136/annrheumdis-2016-210770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。